The role of curcumin as a radiosensitiser in patients receiving radiation for head and neck squamous cell cancers and to find its effectiveness in reducing mucositis in patients receiving radiotherapy for head and neck squamous cell cancers

Not Applicable

Completed

• Conditions: Adjunct to radiotherapy in patients with head and neck squamous cell cancer; Cancer; Oral carcinoma, Radiation, Chemoradiation, Radiosensitiser, Curcumin, Mucositis

• Registration Number: ISRCTN13817594
• Lead Sponsor: Sri Devaraj Urs Medical College

Brief Summary

2020 results in https://www.ncbi.nlm.nih.gov/pubmed/32029014 (added 18/03/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2014-06-01
• Study Start: 2017-11-11
• Last Update Posted: 6 April 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 61

Inclusion Criteria

All adult patients undergoing radiotherapy or concurrent chemo-radiotherapy for Head and Neck Squamous Cell Carcinoma
2. Aged 30- 90 years old

Exclusion Criteria

1. Patients with Non Squamous Head and Neck cancers, patients not giving consent for the treatment
2. Patients with severe acid-peptic disease
3. Patients with distant metastasis
4. Patients with recurrent tumors

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<br> 1. Tumor response is measured using the RECIST criteria using contrast enhanced computerized tomography (CECT) scan at three months<br> 2. Effect of curcumin on oral mucositis is measured using the NCI-CTAE and WHO criteria for mucositis on a weekly basis during treatment and 2 months after treatment for subjective and Objective Assessment respectively<br>

Secondary Outcome Measures

Name	Time	Method
There are no secondary outcome measures.